VISTA is associated with immune infiltration and predicts favorable prognosis in TNBC

被引:6
作者
Zhang, Mi [1 ]
Zhang, Juan [1 ]
Liu, Na [1 ]
Wang, Biyuan [1 ]
Zhou, Yan [1 ]
Yang, Jin [1 ]
机构
[1] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Med Oncol, Xian, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
VISTA; triple-negative breast cancer (TNBC); prognosis; immune infiltration; M1; macrophages; ACQUIRED-RESISTANCE; CHECKPOINT; THERAPY;
D O I
10.3389/fonc.2022.961374
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundV-domain Ig-containing suppressor of T cell activation (VISTA), a critical immune checkpoint protein, can regulate the immune system. Nevertheless, little information is available on the expression level of VISTA and its clinical significance as well. The immunological and prognostic role of VISTA in triple-negative breast cancer (TNBC) still remains unclear. MethodsThe clinical significance and expression of VISTA in TNBC were examined using RNA sequencing and clinical data. Cancer single-cell state atlas (CancerSEA), gene set enrichment analyses (GSEA), single sample GSEA, ESTIMATE algorithm, immunohistochemistry (IHC) were utilized to assess the functions of VISTA. ResultsVISTA was down-regulated and closely associated with good prognosis in TNBC. The expression of VISTA was higher in Immunity-H group and immunomodulatory (IM) subtype. The level of VISTA expression in TNBC gradually increased with the degree of stromal tumor infiltrating lymphocytes (sTILs) infiltration. In addition, the high expression of VISTA was strongly linked to higher proportion of CD8 (+) T cell and M1 macrophages. ConclusionVISTA was remarkably correlated with a favorable prognosis and high immune infiltration in patients with TNBC.
引用
收藏
页数:11
相关论文
共 50 条
  • [11] Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population
    Imai, K
    Matsuyama, S
    Miyake, S
    Suga, K
    Nakachi, K
    [J]. LANCET, 2000, 356 (9244) : 1795 - 1799
  • [12] Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies
    Jiang, Yi-Zhou
    Ma, Ding
    Suo, Chen
    Shi, Jinxiu
    Xue, Mengzhu
    Hu, Xin
    Xiao, Yi
    Yu, Ke-Da
    Liu, Yi-Rong
    Yu, Ying
    Zheng, Yuanting
    Li, Xiangnan
    Zhang, Chenhui
    Hu, Pengchen
    Zhang, Jing
    Hua, Qi
    Zhang, Jiyang
    Hou, Wanwan
    Ren, Luyao
    Bao, Ding
    Li, Bingying
    Yang, Jingcheng
    Yao, Ling
    Zuo, Wen-Jia
    Zhao, Shen
    Gong, Yue
    Ren, Yi-Xing
    Zhao, Ya-Xin
    Yang, Yun-Song
    Niu, Zhenmin
    Cao, Zhi-Gang
    Stover, Daniel G.
    Verschraegen, Claire
    Kaklamani, Virginia
    Daemen, Anneleen
    Benson, John R.
    Takabe, Kazuaki
    Bai, Fan
    Li, Da-Qiang
    Wang, Peng
    Shi, Leming
    Huang, Wei
    Shao, Zhi-Ming
    [J]. CANCER CELL, 2019, 35 (03) : 428 - +
  • [13] Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
    Kakavand, Hojabr
    Jackett, Louise A.
    Menzies, Alexander M.
    Gide, Tuba N.
    Carlino, Matteo S.
    Saw, Robyn Pm
    Thompson, John F.
    Wilmott, James S.
    Long, Georgina V.
    Scolyer, Richard A.
    [J]. MODERN PATHOLOGY, 2017, 30 (12) : 1666 - 1676
  • [14] Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma
    Kondo, Yuta
    Ohno, Tatsukuni
    Nishii, Naoto
    Harada, Kiyoshi
    Yagita, Hideo
    Azuma, Miyuki
    [J]. ORAL ONCOLOGY, 2016, 57 : 54 - 60
  • [15] VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival
    Kuklinski, Lawrence F.
    Yan, Shaofeng
    Li, Zhongze
    Fisher, Jan L.
    Cheng, Chao
    Noelle, Randolph J.
    Angeles, Christina V.
    Turk, Mary Jo
    Ernstoff, Marc S.
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (07) : 1113 - 1121
  • [16] Checkpoint Inhibitors in Triple-Negative Breast Cancer (TNBC): Where to Go From Here
    Kwa, Maryann J.
    Adams, Sylvia
    [J]. CANCER, 2018, 124 (10) : 2086 - 2103
  • [17] TIMER2.0 for analysis of tumor-infiltrating immune cells
    Li, Taiwen
    Fu, Jingxin
    Zeng, Zexian
    Cohen, David
    Li, Jing
    Chen, Qianming
    Li, Bo
    Liu, X. Shirley
    [J]. NUCLEIC ACIDS RESEARCH, 2020, 48 (W1) : W509 - W514
  • [18] VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy
    Lines, J. Louise
    Sempere, Lorenzo F.
    Broughton, Thomas
    Wang, Li
    Noelle, Randolph
    [J]. CANCER IMMUNOLOGY RESEARCH, 2014, 2 (06) : 510 - 517
  • [19] VISTA Is an Immune Checkpoint Molecule for Human T Cells
    Lines, J. Louise
    Pantazi, Eirini
    Mak, Justin
    Sempere, Lorenzo F.
    Wang, Li
    O'Connell, Samuel
    Ceeraz, Sabrina
    Suriawinata, Arief A.
    Yan, Shaofeng
    Ernstoff, Marc S.
    Noelle, Randolph
    [J]. CANCER RESEARCH, 2014, 74 (07) : 1924 - 1932
  • [20] Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
    Liu, Jun
    Yuan, Ying
    Chen, Wenna
    Putra, Juan
    Suriawinata, Arief A.
    Schenk, Austin D.
    Miller, Halli E.
    Guleria, Indira
    Barth, Richard J.
    Huang, Yina H.
    Wang, Li
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (21) : 6682 - 6687